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  Obesity Management: Clinical 
Review and Update of the 
Pharmacologic Treatment Options
Raymond A. Plodkowski, MD; Megan E. McGarvey, MD; Keith Reisinger-Kindle; Bradley Kramer;  
Erik Nelson, DO; Jennifer Lee, DO; and Quang T. Nguyen, DO 
The toolbox of medications available for medical weight management is more robust than ever 
and includes a wide variety of mechanisms of actions and options for patients.
O
ver the past decade the preva-
lence of obesity as defined 
by a body mass index (BMI) 
≥ 30 kg/m2 has significantly 
increased. In the U.S. more than 
78 million adults are estimated to be 
obese.1 The World Health Organiza-
tion projects that by 2025 up to half 
the U.S. population will be obese. 
Cardiovascular disease (CVD) and 
diabetes mellitus (DM) are the main 
comorbid conditions that are com-
plicated by obesity. Initial weight loss 
of 5% to 10% of total body weight 
reduces CVD risk factors, prevents or 
delays the development of type 2 DM 
(T2DM) and improves the health 
consequences of obesity.2 
To date, public health initiatives 
that have focused on obesity preven-
tion and lifestyle intervention have 
had marginal success. In recent years, 
anti-obesity drug therapies have had 
a limited role in clinical treatment 
algorithms. In 2013, the American 
Medical Association acknowledged 
obesity as a disease. In turn, this 
acknowledgement allowed the rec-
ognition of anti-obesity drugs as ac-
ceptable therapeutic adjuncts to 
intensive lifestyle intervention that 
could address the growing obesity 
endemic.
In the past, medications for 
weight reduction were limited. Sev-
eral that were FDA approved had to 
be removed from the market due to 
safety concerns. With few approved 
options, clinicians often had to re-
sort to off-label use of medications. 
However, the landscape has changed 
with 4 new medications gaining re-
cent FDA approval. This review cov-
ers older available medications and 
the newer medications that are now 
available.
SYMPATHOMIMETICS
Sympathomimetic drugs have been 
approved for use as a pharmaco-
logical method to lose weight since 
1960. Of the many versions of this 
drug class that have been available 
since then, there are 4 major versions 
available today. These include dieth-
ylpropion3 and benzphetamine,4 both 
approved in 1960; phendimetrazine, 
approved in 1976;5 phentermine, ap-
proved in 1980;6 and phentermine 
hydrochloride, approved in 2012.7 
Despite the existence of several other 
classes of drugs to treat obesity, phen-
termine remains the most often pre-
scribed weight loss drug in the U.S.8 
Although the mechanism of action 
(MOA) of sympathomimetic drugs 
is not particularly clear, weight loss 
from these medications is believed 
to be due to the increase in the re-
lease of biogenic amines (mainly 
norepinephrine, but also possibly 
dopamine), from storage sites in 
nerve terminals. It is possible that 
these drugs slow catecholamine me-
tabolism by inhibiting the actions of 
monoamine oxidase. The resulting 
increase in amine availability, particu-
larly in the lateral hypothalamic feed-
ing center, is associated with reduced 
food intake. Interestingly, injection 
of these drugs into the ventromedial 
satiety center dooes not seem to sup-
press food intake, and the effects of 
Dr. Plodkowski is a former chief of endocrinology and Dr. Nguyen was an endocrinologist at the VA 
Sierra Nevada Health Care System in Reno. Dr. Plodkowski and Dr. McGarvey are endocrinologists in 
the Division of Endocrinology at Scripps Clinic in San Diego, and Dr. McGarvey is also the associate 
program director of the Endocrinology Fellowship at Scripps Clinic. Dr. Nguyen is currently the medical 
director of Las Vegas Endocrinology and an adjunct associate professor of medicine at Touro University 
Nevada College of Osteopathic Medicine, both in Nevada, and a clinical associate professor of clinical 
education at Arizona College of Osteopathic Medicine in Glendale, California. Mr. Reisinger-Kindle and 
Mr. Kramer are medical students at Touro Univeristy of Osteopathic Medicine. Dr. Nelson and Dr. Lee 
are medical resident at Valley Hospital Medical Center/Touro University.
www.fedprac.com
biogenic amines on increasing me-
tabolism does not seem to play a sig-
nificant role in weight loss in patients 
on these medications.9 
Each of these drugs is rapidly ab-
sorbed from the gastrointestinal (GI) 
tract except for phentermine hydro-
chloride, the newest of the medi-
cations in this class. Phentermine 
hydrochloride is a sublingual tablet 
that is readily absorbed through the 
buccal mucosa.5 All of the drugs in 
this class are excreted through the 
kidneys, with varying rates. Each 
drug’s excretion is highly depen-
dent on the pH of the urine—more 
alkaline conditions result in less ex-
cretion and more acidic conditions 
result in more excretion. As a result, 
these drugs should be used with cau-
tion in patients with renal impair-
ment; however, there are no specific 
contraindications listed for patients 
with poor renal function. 
The adverse effects (AEs) for this 
drug class are to be expected from 
an increase in the release of bio-
genic amines in the central nervous 
system (CNS). The most common 
AEs include palpitations, tremors, 
restlessness, insomnia, dry mouth, 
constipation, diaphoresis, changes in 
libido, and irritability. The more dan-
gerous AEs that have been observed 
include arrhythmias, hypertension, 
dependency/abuse, convulsions, 
acute transient ischemic colitis, and 
acute urinary retention second-
ary to increased bladder sphincter 
tone, transient hyperthyroxemia, and 
paranoia.10
Several contraindications exist for 
sympathomimetics, including the 
presence of advanced arteriosclero-
sis, symptomatic CVD, moderate to 
severe hypertension, hyperthyroid-
ism, glaucoma, patients in an agi-
tated state, or those with a history of 
amphetamine abuse. The warnings 
for prescribers include pulmonary 
hypertension and cardiomyopathy 
secondary to chronic use of sym-
pathomimetics, and valvular heat 
disease secondary to use of sympa-
thomimetics with additional anorec-
tic agents. 
Additional precautions should be 
considered in those with a history of 
anxiety/psychosis, those who operate 
machinery and motor vehicles, and 
even those with mild hypertension. 
The data surrounding the effects of 
sympathomimetics on blood pres-
sure (BP) appears to be conflicting 
and the relationship does not seem 
to have been significantly studied in 
depth to warrant any definitive con-
clusions. The MOA of this drug class 
itself is enough to urge caution to 
prescribers.11 Special attention should 
be given to patients with diabetes 
when using sympathomimetics. A 
reduction of insulin dose or oral hy-
poglycemic dose may be necessary in 
some people with diabetes. 
Only diethylpropion is pregnancy 
category B, whereas the others drugs 
in this class are pregnancy category 
X. It has been demonstrated that di-
ethylpropion and benzphetamine are 
secreted into breastmilk; insufficient 
data exist to suggest whether or not 
phentermine and phendimetrazine 
are present in breastmilk. All drugs in 
this class should be used in caution 
with breastfeeding mothers. 
Although all 4 drugs are regis-
tered as controlled substances, benz-
phetamine and phendimetrazine are 
schedule III and phentermine and di-
ethylpropion are schedule IV, despite 
evidence suggesting the potential for 
abuse to be extremely low.12,13 Phen-
termine has been approved for adults 
aged > 18 years, phendimetrazine 
has been approved for those aged 
> 17 years, diethylpropion has been 
approved for those aged > 16 years, 
and benzphetamine has been ap-
proved for those aged > 12 years. 
There is a wealth of literature 
surrounding the effectiveness of 
this drug class for weight loss. One 
of the longest trials of phentermine 
was recently conducted as part of the 
initial component of a FDA study 
for the newly approved topiramate-
phentermine combination. Weight 
loss at 6 months in the phentermine-
only group was significantly higher 
at -5.8% compared with -1.5% with 
the placebo group in the last observa-
tion carried forward-Intent to treat 
(LOCF-ITT) analysis.14 Similarly, a 
long-term study looking at diethyl-
propion examined the use of dieth-
ylpropion for up to a year vs placebo. 
Participants administered diethyl-
propion lost a mean 9.8% of original 
weight vs 3.7% in the placebo group 
in the first 6 months alone.15
Several meta-analyses and review 
papers have been authored that ex-
amine and analyze the published data 
on this drug class overall and com-
paratively within this class. Haddock 
and colleagues in 2002 reviewed the 
numerous clinical trials associated 
with each drug in this class, in ad-
dition to several other classes, and 
found that although each drug dem-
onstrated a significant advantage vs 
placebo in weight loss, there was not 
a specific drug that was significantly 
superior to any of the others.16 
These results seem to be in rela-
tive agreement with additional stud-
ies like that published by Suplicy 
and colleagues, which demonstrated 
that several sympathomimetics 
were better than placebo in weight 
loss, and that there was little differ-
ence between the specific drugs in 
the class.17 However, it should be 
noted that as highlighted in a review 
by Ioannides-Demos and colleagues 
in 2005, the vast majority of stud-
ies that had been performed on this 
drug class focused on short-term use 
(< 16 weeks) and none of the 
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sympathomimetics listed here have 
been approved for long-term use.18
ORLISTAT
Orlistat 120 mg was approved in 
1999 as a reversible inhibitor of GI 
lipases that specifically reduced the 
absorption of dietary fat due to the 
inhibition of triglyceride hydrolysis.19 
Orlistat was later approved in 2007 
for release in a reduced dosage form 
(60 mg) for over-the-counter sales.20
Orlistat forms a covalent bond 
with the active serine residue site of 
gastric and pancreatic lipases in the 
lumen of the stomach and small in-
testine. The inhibition of these en-
zymes causes dietary fat to remain 
undigested as triglycerides, which 
cannot be converted to absorbable 
free fatty acids and monoglycerides, 
leading to decreased calorie absorp-
tion. Orlistat is not systemically ab-
sorbed and is eliminated mainly 
through feces. Some metabolism oc-
curs in the GI wall.21
Orlistat is most known for its 
GI AEs. Because it is most active in 
the lumen of the GI system and re-
duces the absorption of triglycerides, 
many AEs are related to malabsorp-
tion. The most common issues 1 year 
after starting the drug were oily 
spotting (26.6% vs 1.3% placebo); 
flatus with discharge (23.9% vs 
1.4% placebo); fecal urgency (22.1% 
vs 6.7% placebo); fatty/oily stool 
(20% vs 2.9% placebo); increased 
defecation (10.8% vs 4.1% placebo); 
and fecal incontinence (7.7% vs 
0.9% placebo) (Table 1). Most of 
these AEs were greatly reduced after 
taking the drug for 2 years. Orlistat 
also has more serious AEs noted, in-
cluding abdominal pain/discomfort; 
nausea; infectious diarrhea; rectal 
pain/discomfort; tooth disorder; 
gingival disorder; vomiting; upper 
respiratory infection; lower respira-
tory infection; ear, nose and throat 
symptoms; back pain; arthritis; my-
algia; joint disorders; tendonitis; 
headache; dizziness; fatigue; sleep 
disorders; rash; dry skin; menstrual 
irregularity; vaginitis; urinary tract 
infection; and psychiatric disorders, 
although these did not differ mark-
edly from placebo. 
One of the most serious AEs re-
ported was fulminate hepatic failure, 













Maintenance Dose 16 mg/180 mg bid 3 mg qd 10 mg bid 120 mg tid 7.5 mg/46 mg qd
Medication Control Medication Control Medication Control Medication Control Medication Control
Age, y 44.4 43.7 45.2 45.0 43.8 43.7 43.2 41.6 51.1 51.2
Gender (% female) 85 85 78.7 78.1 80.5 78.0 79 78 70.0 70.0
Baseline weight, kg 99.7 99.5 106.2 106.2 100.1 100.5 100.5 101.8 102.6 103.3
Baseline waist  
circumference, cm
108.8 110.0 115.0 114.5 108.9 110.2 n/a n/a 112.6 113.4
Baseline BMI 36.1 36.2 38.3 38.3 36.0 35.9 36.0 36.1 36.2 36.7
Completers weight 
loss, %
-8.0 -1.9 -9.2 -3.5 -7.9 -4.0 -8.78 -4.26 -9.6 -1.6
LOCF weight 
loss, %
-6.1 -1.4 -8.0 -2.6 -5.8 -2.8 -7.94 -4.14 -8.1 -1.4
≥ 5% LOCF weight 
loss, % 
48 16 63.2 27.1 47.2 25.0 50.5 30.7 62 21
≥ 10% LOCF 
weight loss, %
25 7 33.1 10.6 22.6 9.7 28.6 11.3 37 7
Abbreviations: BMI, body mass index; LOCF, last observation carried forward.
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though this AE is rare. Thirteen cases 
of liver injury were reported with the 
120-mg prescription dose of orlistat 
and 1 case report in the U.S. involved 
the 60-mg over-the-counter dosage 
of orlistat.21,22 The FDA suggests that 
patients talk to their physicians about 
risks of liver failure, and that physi-
cians should educate their patients 
about signs and symptoms of liver 
failure so that patients can stop tak-
ing orlistat and seek immediate medi-
cal help if symptoms occur.
One of the first published trials 
was the European Multicentre Or-
listat Study Group, which included 
743 participants with BMI between 
28 kg/m2 and 47 kg/m2 from 15 dif-
ferent European centers. To test 
adherence, a 4-week single blind 
placebo lead-in was started with a 
hypocaloric diet. The first stage was 
completed by 688 patients who then 
proceeded to the double blind ran-
domized control trial portion with 
a hypocaloric diet. From the start of 
lead-in to the end of year 1, the or-
listat group weight decreased 10.2% 
(10.3 kg) vs 6.1% (6.1 kg) in the pla-
cebo group. The placebo subtracted 
difference between the groups was 
3.9 kg (P < .001).23
A U.S.-based randomized double-
blind placebo-controlled multicenter 
study included 796 obese patients 
with BMI between 30 kg/m2 and 
44 kg/m2. Patients were assigned to 1 
of 3 groups: placebo, orlistat 60 mg 3 
times daily, or orlistat 120 mg 3 times 
daily. All groups were given a re-
duced energy diet. Patients in the or-
listat 120 mg group lost significantly 
more weight than did the placebo 
group, -8.78% vs -4.26% respectively 
in year 1 in the completer analysis 
(P = .001). More participants who 
were treated with orlistat 120 mg lost 
5% or more of their initial weight in 
year 1 compared with placebo, 50.5% 
vs 30.7% respectively (P < .001).24 
In the XENDOS study the pri-
mary outcome measurement was 
time to onset of T2DM. Eligible par-
ticipants were aged 30 to 60 years, 
with a BMI > 30 kg/m2. All patients 
had a 75-g oral glucose tolerance test 
and were required to have normal 
glucose tolerance or impaired glucose 
tolerance, but not T2DM. The dou-
ble-blind randomized controlled trial 
included 3,305 subjects and com-
pared a group taking 120 mg orlistat 
3 times daily vs placebo. All patients 
were prescribed a reduced-calorie 
diet (800 kcal/d deficit) containing 
30% of calories from fat. Patients 
were also encouraged to walk at least 
1 kilometer daily in addition to their 
usual physical activity. Incidence 
of T2DM after 4 years was 6.2% in 
the orlistat group and 9.0% in the 
placebo group, reflecting a 37.3% 
risk reduction in the orlistat group 
(P = .0032).25,26
LORCASERIN
In 2012, lorcaserin HCl was FDA ap-
proved as a schedule IV drug for use 
as a weight loss medication as an ad-
junct to a reduced-calorie diet and 
increased physical activity. Lorcaserin 
is thought to act on 5-hydroxytryp-
tamine-2c (5HT2c) receptors on the 
pro-opiomelanocortin (POMC) neu-
rons in the arcuate nucleus, causing 
release of alpha-melanocortin-stimu-
lating hormone (alpha-MSH), which 
in turn acts on melanocortin-4 recep-
tors in the paraventricular nucleus to 
suppress appetite. At the maximum 
suggested dose of 10 mg twice daily, 
lorcaserin binds with 15 to 100 times 
greater affinity to 5HT2c receptors 
compared with 5HT2a and 5HT2b 
receptors respectively. 
Indications for lorcaserin include 
patients with BMI ≥ 30 kg/m2 or 
≥ 27 kg/m2 or greater with a weight-
related comorbid condition such as 
hypertension, dyslipidemia, cardio-
vascular disease, impaired glucose 
tolerance, or sleep apnea.
The efficacy of lorcaserin for 
weight loss has been evaluated in 
3 separate trials. The trials were ran-
domized, double blinded and pla-
cebo controlled. The BLOOM trial, 
which included 3,182 patients with 
a mean BMI of 36.2 kg/m2, evaluated 
the efficacy of lorcaserin as a weight 
loss adjunct.27 Patients with pre- 
existing valvular disease, uncon-
trolled hypertension, or a major 
psychiatric condition were ex-
cluded. After initial randomization, 
patients were assigned to receive 
either lorcaserin 10 mg twice daily 
or a placebo. The primary endpoint 
was a 5% weight reduction from 
baseline  by the end of 2 years. At 
1 year, 47.5% of patients in the lor-
caserin group and 20.3% in the pla-
cebo group had lost ≥ 5% of their 
body weight (P <.001). The aver-
age loss for the lorcaserin group was 
5.8 ± 0.2 kg and 2.2 ± 0.1 kg for the 
placebo group at 1 year (P < .001).
The BLOSSOM trial was a 1-year 
study of 4,008 patients aged 18 to 
65 years. The trial evaluated the ef-
fects of lorcaserin on body weight, 
CVD risk factors, and safety in obese 
and overweight patients.28 Patients 
were randomized in a 2:1:2 ratio to 
receive lorcaserin 10 mg twice daily, 
lorcaserin 10 mg once daily, or pla-
cebo. The primary endpoint was the 
proportion of patients achieving at 
least 5% reduction in body weight. 
Completer analysis showed weight 
reduction in the placebo group was 
4.0% and 7.9% in the lorcaserin group 
(P < .001). In the modified intent-to-
treat/last observation carried forward 
analysis (MITT/LOCF), a statistically 
significant 47.2% of patients receiv-
ing lorcaserin 10 mg twice daily and 
40.2% of patients receiving lorcaserin 
10 mg once daily lost at least 5% of 
baseline body weight; compared with 
10 • FEDERAL PRACTITIONER • JANUARY 2016
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25% of patients receiving placebo 
(P < .001). Weight loss of at least 10% 
was achieved by 22.6% of patients re-
ceiving lorcaserin 10 mg twice daily, 
and 17.4% of patients receiving 10 mg 
daily compared with 9.7% of patients 
in the placebo group (P < .001). 
The most common AEs noted 
were headache, nausea, and dizzi-
ness. Echocardiographic evidence of 
valvulopathy occurred in 2% of pa-
tients taking lorcaserin 10 mg twice 
daily and those taking the placebo. 
Lorcaserin administered in conjunc-
tion with a diet and exercise program 
was associated with an overall reduc-
tion in baseline BMI when compared 
with placebo over the year. 
The BLOOM-DM study evalu-
ated efficacy and safety of lorcaserin 
for weight loss in 604 patients with 
T2DM over the course of 1 year.29 
Patients had a hemoglobin A1c (A1c) 
of 7% to 10% and were treated with 
metformin, a sulfonylurea, or both. 
The primary endpoint was a 5% 
weight reduction from baseline at the 
end of 1 year. Patients were random-
ized into 3 groups: 1 group received 
lorcaserin 10 mg twice daily, 1 group 
took lorcaserin 10 mg daily, and 
1 group received the placebo. A sta-
tistically significant 37.5% of patients 
taking lorcaserin 10 mg twice daily 
achieved > 5% body weight reduction, 
compared with 44.7% in the lorcase-
Table 2. Recent FDA-Approved Pharmacologic Obesity Treatments
Drug (Brand) Mode of Action
Maintenance 
Dose
Weight Loss vs 
Placebo, %
Significant  
Adverse Event vs 
Placebo
Discontinuation 
Rate vs  
Placebo, %









16 mg/180 mg 
BID

















9.9% vs. 3.8% Use with caution in 
moderate to severe 




Serotonin 2C  
receptor agonist
10 mg BID 5.8 vs 2.8 Nausea:  
9.4% vs. 7.9%




22.1% vs. 37.9% Use with caution in 
moderate to severe 






120 mg TID 7.9 vs 4.2 Oily spotting:  
26.6% vs. 1.3%
















Dry mouth:  
13.7% vs. 2.2%
11.6% vs 8.4% Use with caution in 
moderate to severe 
renal impairment or 
hepatic impairment
Obesity ManageMent
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rin 10 mg daily group, and 16.1% in 
the placebo group. Overall reductions 
in A1c and fasting glucose were ob-
served in both lorcaserin groups tak-
ing as compared with placebo. Patient 
A1c decreased 0.9 ± 0.06 with lorcase-
rin 10 mg bid, 1.0 ± 0.09 with lorcase-
rin 10 mg qd, and 0.4 ± 0.06 with the 
placebo (P < .001). Fasting glucose in 
the lorcaserin bid, lorcaserin qd, and 
placebo groups decreased 27.4 ± 2.5 
mg/dL, 28.4 ± 3.8 mg/dL, and 11.9 
± 2.5 mg/dL, respectively (P < .001). 
Symptomatic hypoglycemia occurred 
in 7.4% of patients on lorcaserin bid, 
10.5% on lorcaserin qd, and 6.3% on 
placebo. Headache, back pain, naso-
pharyngitis, and nausea were among 
the most commonly reported AEs. 
As lorcaserin is a serotonergic ago-
nist, potential interactions exist when 
used with other medications affecting 
serotonin. Most notably, serotonin 
syndrome and neuroleptic malignant 
syndrome-like reactions may occur. 
Because of this, it is recommended 
to avoid selective serotonin re-uptake 
inhibitors (SSRIs), selective norepi-
nephrine reuptake inhibitors, tri-
cyclic antidepressants, bupropion, 
triptans, monoamine oxidase inhibi-
tors, lithium, dextromethorphan, 
and dopamine agonists. Lorcaserin 
seems to be safe in those patient pop-
ulations with mild hepatic as well as 
mild renal impairment; however, it 
is not recommended for those with 
severe renal impairment. Given the 
multiple enzymatic pathways used to 
metabolize lorcaserin, there is a low 
probability for cytochrome drug in-
teractions. Safety has not been well 
evaluated in patients aged < 18 years 
and those that are pregnant (preg-
nancy category X).
Adverse events include headache, 
dizziness, fatigue, nausea, and dry 
mouth. Other notable AEs include 
nasopharyngitis and URI. Hypoglyce-
mia appeared to be more common in 
patients with DM taking lorcaserin. 
Cognitive impairment and psychiat-
ric disorders including euphoria and 
hallucinations were also reported. 
Notably, valvular heart disease has 
been reported in patients who take 
medications with 5HT2b activity. In 
a 1-year clinical trial, a small num-
ber of patients were found to develop 
valvular regurgitation. Furthermore, 
bradycardia, priapism, leucopenia, el-
evated prolactin, and pulmonary hy-
pertension have also been observed. 
Caution is recommended if symp-
toms of any of the aforementioned 
conditions are noticed. 
QSYMIA
The schedule IV controlled substance 
Qsymia (Vivus, Mountain View, CA) 
is a combination of phentermine, an 
anorexigenic agent, and topiramate 
extended-release, an antiepileptic 
drug. In July of 2012 it was approved 
for chronic weight management as 
an addition to a reduced-calorie diet 
and exercise. The drug is approved 
for adults with a BMI ≥ 30 kg/m2 or 
adults with a BMI ≥ 27 kg/m2 who 
have at least 1 weight-related condi-
tion such as hypertension, T2DM, or 
dyslipidemia.30 
In 1996 topiramate was approved 
by the FDA for the treatment of 
seizure disorders and was also ap-
proved for migraine prophylaxis in 
2004. In patients who were treated 
with topiramate for seizure disor-
ders and migraines, weight loss and 
a reduction in visceral body fat has 
been observed.31 The precise MOA of 
topiramate in regards to weight loss 
is not fully understood. It may be due 
to its effects on both appetite sup-
pression and satiety enhancement. 
Topiramate exhibits a combination 
of properties including modulatory 
effects on sodium channels, enhance-
ment of GABA-activated chloride 
channels, inhibition of excitatory 
neurotransmission through actions 
on kainite and AMPA receptors, and 
inhibition of carbonic anhydrase 
(CA) isoenzymes in particular CA II 
and IV.14 
The combination of phentermine 
and topiramate is a once-daily for-
mulation that is designed to provide 
an immediate release of phentermine 
and a delayed release of topiramate, 
allowing a peak exposure of the 
phentermine in the morning and a 
peak concentration of topiramate in 
the evening. It should be taken in the 
morning in order to avoid the pos-
sibility of insomnia that can occur if 
taken in the evening. It can be taken 
with or without food. The recom-
mended dose is as follows: Start treat-
ment with Qsymia 3.75 mg/23 mg 
extended-release daily for 14 days; 
after 14 days increase to the recom-
mended dose of Qsymia 7.5 mg/ 
46 mg once daily. 
Weight loss should be evaluated 
after 12 weeks at the higher dose. If 
at least 3% of baseline body weight 
has not been lost at that time, dis-
continue or escalate the dose. To es-
calate the dose: Increase to Qsymia 
11.25 mg/69 mg daily for 14 days; 
followed by Qsymia 15 mg/92 mg 
daily. Evaluate weight loss following 
dose escalation to Qsymia 15 mg/ 
92 mg after an additional 12 weeks 
of treatment. If at least 5% of base-
line body weight has not been lost 
on Qsymia 15 mg/92 mg, discon-
tinue as directed. It is important not 
to suddenly discontinue, as this may 
cause seizures. Patients should be 
slowly titrated off the medication.
In vitro studies of phenter-
mine and topiramate indicate that 
these drugs are not likely to cause 
clinically significant interactions 
with drugs using the cytochrome 
P450 enzyme pathways, or those 
involved in plasma protein binding 
displacement; however there is evi-
12 • FEDERAL PRACTITIONER • JANUARY 2016
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dence suggesting that ethinyl estra-
diol levels may be decreased by 16%, 
thus raising a concern about the pos-
sibility of decreased contraceptive 
efficacy.31 In patients with moderate 
(creatine clearance ≥ 30 mL/min to 
< 50 mL/min) and severe renal dys-
function (< 30 mL/min), the maxi-
mum dose of should not exceed 
7.5 mg/46 mg.
Qsymia was evaluated in 3 phase 
3 trials for its long-term efficacy 
and safety. In all trials, diet and life-
style counseling were provided for 
all patients. The first of these stud-
ies was OB-301, a 28-week confir-
matory trial with a factorial design 
involving 7 treatment arms, tested 
2 fixed-dose Qsymia combinations—
regular dose (7.5 mg/46 mg) and 
maximum dose (15 mg/92 mg)—as 
well as regular and maximum doses 
of the individual constituent drugs 
vs placebo.32 The study randomized 
756 obese patients with a BMI range 
of 30 kg/m2 to 45 kg/m2 to 1 of the 
7 treatment arms for 28 weeks. Pa-
tients treated with maximum-dose 
Qsymia achieved an average weight 
change of -9.0%, vs -1.5% with pla-
cebo (P < .0001). Weight change 
with regular-dose Qsymia was -8.2%. 
Weight changes with monotherapies 
were: -6.1% with topiramate 92 mg, 
-4.9% with topiramate 46 mg, -5.8% 
with phentermine 15 mg, and -5.2% 
with phentermine 7.5 mg.
OB-302 was a 56-week trial that 
randomized 1,267 morbidly obese 
patients with a BMI ≥ 35 kg/m2 with-
out significant comorbidities to 
low-dose Qsymia (3.7 mg/23 mg), 
maximum-dose Qsymia (15 mg/ 
92 mg), or placebo.33 At baseline, the 
mean BMI for the entire study cohort 
was 42 kg/m2. Mean weight changes 
were -1.6% with placebo, -5.1% with 
low-dose Qsymia, and -10.9% with 
maximum-dose Qsymia. The pro-
portions of patients achieving ≥ 5% 
weight loss were: 17% with placebo, 
45% with low-dose Qsymia, and 67% 
with maximum-dose Qsymia.
CONQUER was the largest of the 
phase 3 trials. It randomized 2,487 
overweight or obese patients with 
a BMI of 27 kg/m2 to 45 kg/m2 and 
≥ 2 obesity-related comorbidities 
(hypertension, dyslipidemia, T2DM, 
prediabetes or abdominal obesity) 
to receive a placebo, regular-dose 
Qsymia, or maximum-dose Qsymia 
for 56 weeks.34 In the completer pop-
ulation, mean weight changes in the 
placebo, regular dose Qsymia, and 
maximum-dose Qsymia groups were 
-1.6%, -9.6% (P <.0001), and -12.4% 
(P < .0001);  and weight loss of ≥ 5% 
was achieved by 21%, 62%, and 70%, 
respectively. Relative to placebo, there 
were greater reductions in systolic BP, 
triglycerides, and fasting insulin with 
both doses of Qsymia. 
Patients should not take Qsymia 
if they are pregnant, planning to 
become pregnant, or become preg-
nant during Qsymia treatment as 
there is an increased risk of birth 
defects, namely cleft lip and cleft 
palate. Women who can become 
pregnant should have a nega-
tive pregnancy test before taking 
Qsymia and every month while on 
the medication. They should use 
effective birth control consistently 
while taking Qsymia.
Qsymia is contraindicated in pa-
tients with glaucoma and patients 
who have hyperthyroidism. Qsymia 
can cause an increase in resting heart 
rate and regular monitoring of rest-
ing heart rate is recommended, es-
pecially in patients with cardiac or 
cerebrovascular disease. It has not 
been studied in patients with recent 
or unstable cardiac or cerebrovascu-
lar disease and therefore use is not 
recommended.
Qsymia can cause mood disor-
ders such as anxiety and depression 
and can increase the risk of suicidal 
thoughts. Patients should be moni-
tored for worsening depression, sui-
cidal thoughts or behavior, or any 
unusual changes in mood or behav-
ior. It is not recommended in patients 
with a history of suicidal attempts 
or active suicidal ideation. Qsymia 
can cause cognitive dysfunction. It 
can cause confusion, problems with 
concentration, attention, memory, or 
speech. Patients should be cautioned 
about operating automobiles and 
hazardous machinery.
Normal anion gap hyperchlo-
remic metabolic acidosis has been 
reported in patients treated with 
Qsymia. If this does develop and 
persists, consideration should be 
given to either reduce the dose or 
discontinue Qsymia.
Weight loss may increase the risk 
of hypoglycemia in patients with 
T2DM treated with insulin and/or 
insulin secretagogues (eg, sulfonyl-
ureas). Qsymia has not been stud-
ied in combination with insulin. A 
reduction in the dose of antidiabetic 
medications, which are nonglucose 
dependent, should be considered to 
reduce the risk of hypoglycemia.
The most common AEs in con-
trolled clinical studies (≥ 5% and at 
least 1.5 times placebo) included par-
aesthesia in the hands, arms, feet or 
face, dizziness, dysgeusia, insomnia, 
constipation, and dry mouth.
CONTRAVE
In 2014, the FDA approved Contrave 
(Takeda, Deerfield, IL) as treatment 
option for chronic weight manage-
ment in addition to reduced-calorie 
diet and physical activity. The com-
bination of naltrexone hydrochloride 
and bupropion hydrochloride was 
originally introduced for the treat-
ment of opioid addiction and later 
expanded to include the treatment of 
alcoholism. The antidepressant bu-
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propion was approved in the U.S. in 
1989. It is structurally different from 
all other marketed antidepressants 
(ie, tricyclics, tetracyclics, and SSRIs), 
but closely resembles the structure of 
diethylpropion, an appetite depres-
sant with minimal CNS effects.35
This drug is approved for adults 
with BMI ≥ 30 kg/m2  and for adults 
with BMI > 27 kg/m2  with at least 
1 weight-related risk factors such 
as hypertension, T2DM, or dyslip-
idemia. It should be used as an ad-
junct to diet and exercise and is not 
approved for use for depression even 
though it contains bupropion.
Naltrexone is a pure opioid an-
tagonist with high affinity to μ-opioid 
receptor, which is implicated in eating 
behavior. Naltrexone is rapidly and 
nearly completely absorbed from the 
GI tract after oral administration. The 
time to peak plasma concentration is 
about 1 hour. Naltrexone is well ab-
sorbed but first pass extraction and 
metabolism by the liver decreases oral 
bioavailability to between 5% to 40%. 
Primary elimination of naltrexone 
and its metabolites is renal excretion. 
Bupropion is a weak inhibitor of 
neuronal reuptake of dopamine and 
norepinephrine. This drug is used 
to treat depression and seasonal af-
fective disorder, and aid in smoking 
cessation. Bupropion is absorbed 
rapidly after oral administration, but 
the absolute oral bioavailability of 
bupropion is not known because an 
IV preparation is not available. The 
time to peak plasma concentrations 
of bupropion is within 2 hours of 
oral administration. Bupropion is ex-
tensively metabolized by the liver to 
multiple metabolites. Primary elim-
ination of bupropion is urinary ex-
cretion. However, hepatic and renal 
impairment may affect the elimina-
tion of bupropion and its metabolites. 
Patients with hepatic or renal impair-
ment should use a reduced dosage. 
Combination therapy has been 
found to have complementary ac-
tions on CNS to reduce food intake. 
They are believed to dampen CNS re-
ward pathways, taking away the com-
pulsive feeding behavior and pleasure 
of feeding, ultimately leading to 
weight loss. Bupropion stimulates 
hypothalamic pro-opiomelanocortin 
neurons (POMC), which results in 
reduced food intake and increased 
energy expenditure. Naltrexone 
blocks opioid-receptor mediated 
POMC auto-inhibition, blocks the 
increase in dopamine in nucleus ac-
cumbens that occurs when eating, 
and acting synergistically with bupro-
pion in augmenting POMC firing. 
The COR-I and COR-II trials com-
pared Contrave to diet and exercise 
in patients who did not have DM. 
The COR-Diabetes trial included the 
same study design but focused on pa-
tients with DM. In all the studies the 
participants had a 4-week titration 
to Contrave (naltrexone 8 mg/bu-
propion 90 mg) to decrease nausea. 
The first week dosing was 1 tablet in 
the morning. Week 2 was 1 tablet in 
morning and 1 tablet in the evening. 
In week 3, patients took 2 tablets in 
the morning and 1 tablet in the eve-
ning. The final titration step was 
2 tablets in the morning and 2 tablets 
in the evening. 
The COR-1 study was a 56-week 
randomized, double-blind, placebo-
controlled study. It compared Con-
trave 32 mg naltrexone/360 mg 
bupropion (NB32/360) with an active 
placebo of diet and exercise.36 To be 
included adults must be aged 18 to 
65 years with a BMI 30 kg/m2 to 45 
kg/m2 or a BMI 27 kg/m2 to 45 kg/m2 
with dyslipidemia or hypertension. 
Patients were instructed on a hypo-
caloric diet that was a 500 kcal per 
day deficit based on World Health Or-
ganization algorithm for calculating 
metabolic rate and they were urged to 
increase physical activity. 
The completer population re-
sults showed 8.0% weight loss in 
the NB32/360 group and 1.9% 
weight loss in the placebo group 
(P < .001). For the NB32/360 and pla-
cebo groups, weight loss of ≥ 5% was 
achieved by 48% and 16% (P <.001), 
respectively; and weight loss of ≥ 10% 
by 25% and 7% (P < .001), respec-
tively. The most common AE was 
nausea—29.8% with NB32/360 vs 
5.3% with placebo. Nausea generally 
occurred early and then diminished 
and the discontinuation rate from 
nausea was significantly lower (6.3%) 
then the overall reported nausea rates. 
Contrave was also studied in pa-
tients with T2DM. The COR-Diabe-
tes Trial was a 56-week randomized, 
double blind, placebo-controlled 
study. The trial compared Contrave 
32 mg naltrexone/360 mg bupropion 
(NB32/360) with an active placebo of 
diet and exercise.37 Inclusion criteria 
for the trial were patients aged 18 to 
70 years with T2DM and a BMI from 
27 kg/m2 to 45 kg/m2, A1c between 
7% and 10%, and fasting blood glu-
cose < 270 mg/dL. Participants either 
were not taking a DM medication or 
were on stable doses of oral antidia-
betes drugs ≥ 3 months prior to ran-
domization. Patients were placed on 
a 500 kcal hypocaloric diet and ad-
vised to increase physical activity. 
The results showed 5.0% weight 
loss in the NB32/360 group and 1.8% 
weight loss in the placebo group 
(P < .001). Weight loss of ≥ 5% and 
≥ 10% was achieved by 44.5% and 
18.5% of the NB32/360 group, re-
spectively, and 18.9% and 5.7%, re-
spectively (P < .001) of the placebo 
group. The NB32/360 and placebo 
showed a reduction of A1c of 0.6% 
and 0.1% respectively (P < .001). 
The most common AE was nausea 
(42.3% with NB32/360 vs 7.1% with 
placebo). Nausea generally occurred 
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early and then diminished and the 
discontinuation rate from nausea was 
significantly lower (9.6%) then the 
overall reported nausea rates.37
Due to potential nausea caused by 
naltrexone, Contrave should be ti-
trated over 4 weeks as described ear-
lier. At maintenance dose, patients 
should be evaluated after 12 weeks to 
determine treatment benefits. If a pa-
tient has not lost at least 5% of base-
line body weight, Contrave should 
be discontinued, because it would be 
unlikely that the patient will achieve 
and sustain clinically meaningful 
weight loss with continued treat-
ment. Contrave should not be taken 
with high-fat meals that may result in 
significant increase in bupropion and 
naltrexone systemic exposure. 
Since Contrave contains the anti-
depressant bupropion, it has a boxed 
warning similar to other antidepres-
sants in its class of increased risk 
of suicidal thoughts and behaviors, 
especially in children, adolescents, 
and young adults.38 Contrave can 
lower the seizure threshold; there-
fore it should not be used in people 
with a seizure disorder. It can also 
raise BP and heart rate; however the 
clinical significance of hypertension 
and elevated heart rate observed with 
Contrave treatment is unclear. Blood 
pressure rose on average by 1 point 
during the first 8 weeks of treatment 
and then returned to baseline.38 The 
heart rate also increased by about 
1.7 beats per minute.38 Patients with 
uncontrolled hypertension should 
avoid Contrave.
Contrave should not be taken 
with products contain bupropion or 
naltrexone. It should not be taken 
by patient who are regularly taking 
opioids or who are opioid depen-
dent, or who are experiencing opiate 
withdrawal. Pregnant women should 
also avoid Contrave. In patients with 
renal impairment the maximum dose 
is 1 tablet twice a day and in patients 
with hepatic impairment the maxi-
mum dose is 1 tablet a day. 
LIRAGLUTIDE
Liraglutide is the newest weight loss 
medication to be approved by the 
FDA for chronic weight management 
as an adjunct to a reduced calorie 
diet and increased physical activity 
in adult patients with BMI ≥ 30 kg/
m2 or ≥ 27 kg/m2 with hypertension, 
diabetes, or dyslipidemia. The recom-
mended dose of liraglutide is 3 mg 
daily. The initial dose is 0.6 mg daily 
for the first week, then titrated up 
by 0.6 each week for 4 weeks, until 
reaching 3 mg daily. 
Liraglutide is an acylated human 
glucagon-like peptide-1 (GLP-1) re-
ceptor agonist, which are expressed 
in the brain and is involved in the 
control of appetite. It is also found 
in the beta cells of the pancreas, 
where GLP-1 receptors stimulate in-
sulin release in response to elevated 
blood glucose concentrations and 
suppress glucagon secretion. Endog-
enous GLP-1 has a half-life of 1.5 to 
2 minutes due to degradation by the 
DDP-4 enzyme, but liraglutide is sta-
ble against degradation by peptidases 
and has a half- life of 13 hours. 
Liraglutide was studied in a 
56-week randomized, double-blind, 
placebo-controlled trial, which com-
pared liraglutide 3 mg with an active 
placebo of diet and physical activity.39 
Inclusion criteria were adults aged 
≥ 18 years old with a BMI 30 kg/
m2 to 45 kg/m2 or BMI 27 kg/m2 to 
45 kg/m2 with dyslipidemia and/or 
hypertension. Both groups received 
lifestyle modification counseling. Pa-
tients were excluded if they had DM. 
In the trial, 3,731 participants 
enrolled, 2,487 in the liraglutide 
group and 1,244 in the placebo 
group; 78.7% of the participants 
were female and the average age 
was 45 years. Subjects in the lira-
glutide group had a weekly titration 
regimen. The starting dose at week 
1 was 0.6 mg, week 2 was 1.2 mg, 
week 3 was 1.8 mg, week 4 was 
2.4 mg, and week 5 was 3.0 kg. 
The completer  populat ion 
showed 9.2% weight loss in the lira-
glutide group and 3.0% weight loss 
in the control group.39 Weight loss of 
≥ 5% was seen in 63.2% and 27.1% 
of the liraglutide and placebo groups, 
respectively. Weight loss rates of 
≥ 10% was seen by 33.1% and 
10.6%, respectively. The most com-
mon AEs were nausea, diarrhea, and 
constipation. Nausea generally oc-
curred early during the titration pe-
riod and then diminished. 
A second clinically relevant study 
was performed with liraglutide. Often 
patients are able to lose weight with 
diet and exercise and then plateau. 
This study examined participants 
who lost 5% percent of their initial 
body weight and then were random-
ized to liraglutide or placebo.40  Key 
inclusion criteria were people aged 
≥ 18 years old with a BMI 30 kg/m2 
to 45 kg/m2 or BMI 27 kg/m2 to 45 
kg/m2 with dyslipidemia and/or hy-
pertension. In order to be random-
ized, participants were required to 
lose at least 5% of their initial body 
weight on a 1,200 kcal to 1,400 kcal 
diet with increased physical activity 
during a 4 to 12 week run-in period. 
Four hundred twenty-two partici-
pants were enrolled, 212 in the lira-
glutide group and 210 in the placebo 
group. Most of the participants were 
female (81%). The average BMI in 
the study was 35.6 kg/m2. Subjects 
in the liraglutide group had a weekly 
titration regimen. 
After an average weight loss of 6% 
using a low calorie diet and increased 
physical activity the participants were 
randomized to continue diet and 
increased activity alone (placebo) 
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or with liraglutide. At week 56 the 
results showed an additional 6.2% 
weight loss in the liraglutide group 
and 0.2% weight gain in the placebo 
group. The liraglutide group had a 
greater number of participants with 
≥ 5% weight loss compared to pla-
cebo, 50.5% vs 21.8% (P < .0001).40 
In the pooled data set from the regis-
tration trials the 3 most common GI 
AEs were nausea, diarrhea, and con-
stipation occurring in 39.3%, 20.9%, 
and 19.4% of participants respec-
tively. Discontinuation due to nausea 
for liraglutide was 2.9%.41 
Clinicians should be aware that 
medications that can cause hypo-
glycemia such as sulfonylureas and 
insulin must be tapered as patients 
lose weight with liraglutide. Docu-
mented symptomatic hypoglycemia 
in patients with T2DM and with sul-
fonylurea background therapy was 
43.6% with liraglutide vs 27.3% with 
placebo. 
In the setting of renal impairment, 
patients treated with GLP-1 receptor 
agonists, including liraglutide, have 
had reports of acute renal failure and 
worsening of chronic renal failure 
usually associated with nausea, vom-
iting, diarrhea, or dehydration. Lira-
glutide causes thyroid C-cell tumors 
at clinically relevant exposures in rats 
and mice. It is unknown whether 
liraglutide causes thyroid C-cell tu-
mors, including medullary thyroid 
carcinoma (MTC), in humans. As 
the human relevance of liraglutide-
induced rodent thyroid C-cell tumors 
has not been determined liraglutide 
is contraindicated in patients with a 
personal or family history of MTC or 
in patients with multiple endocrine 
neoplasia syndrome type 2.
Acute pancreatitis, including fatal 
and nonfatal hemorrhagic or necro-
tizing pancreatitis, has been observed 
in patients treated with liraglutide 
in postmarketing reports. After ini-
tiation of liraglutide, observe patients 
carefully for signs and symptoms of 
pancreatitis (including persistent se-
vere abdominal pain, sometimes radi-
ating to the back, which may or may 
not be accompanied by vomiting). If 
pancreatitis is suspected, liraglutide 
should promptly be discontinued.
CONCLUSION
The treatment of obesity and over-
weight with comorbidities has always 
been a challenge. In the past there 
were few FDA-approved drugs and 
many drugs had to be used off-label. 
The toolbox of medications avail-
able for medical weight manage-
ment is more robust than ever. The 
medications have different MOAs 
and can be used in a variety of pa-
tients. There are differences in the 
classes and some are controlled sub-
stances. Phentermine, lorcaserin, and 
Qsymia (phentermine/topiramate) 
are controlled substances whereas 
orlistat, naltrexone/bupropion and 
liraglutide are not. Other differences 
exist including duration of use. The 
sympathomimetic drugs have a lim-
ited window of use whereas orlistat, 
Qsymia (phentermine/topiramate), 
lorcaserin, naltrexone/bupropion, 
and liraglutide do not. 
The medications that are available 
have a wide variety of MOAs. There-
fore, if a patient fails one medica-
tion, then it is very reasonable to try 
a medication with a different MOA. 
In addition, there is the potential for 
weight regain when weight reduc-
tion medications are discontinued. 
As people lose weight their meta-
bolic rate decreases about 15 kcal per 
pound of weight reduction.42
Another challenge of using these 
medications is managing patient ex-
pectations. The current metric used 
for FDA approval is a 5% weight loss 
that is greater in the study group 
compared with the diet and physi-
cal activity active control. However, 
many clinicians and patients do not 
find this weight reduction amount 
consistent with their expectations. 
In addition weight loss trajectory 
may also be too slow for patients 
and cause early discontinuation. 
Therefore, patient education and a 
discussion of reasonable expecta-
tions for weight reduction medica-
tions are necessary. 
Clinicians must acknowledge 
that there are limitations to the use 
of these medications. Newer agents 
do have a higher cost and insur-
ance reimbursement is somewhat 
limited. However, they offer the op-
portunity to prevent more expen-
sive, protracted conditions such as 
diabetes and cardiovascular disease. 
In summary, clinicians now have a 
wider variety of medication options 
to be used with dietary and lifestyle 
changes in order to improve health 
and prevent chronic diseases. l
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formation for specific drugs or drug 
combinations—including indications, 
contraindications, warnings, and 
16 • FEDERAL PRACTITIONER • JANUARY 2016
Obesity ManageMent
www.fedprac.com
adverse effects—before administering 
pharmacologic therapy to patients.
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